Cargando…

Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices

Biosimilars are highly similar but nonidentical biologic agents with no differences in clinical efficacy and safety when compared to bio-originator products. Considering the long-term costs of managing inflammatory bowel disease (IBD), biosimilars, through economic competition, provide an opportunit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhat, Shubha, Qazi, Taha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802378/ https://www.ncbi.nlm.nih.gov/pubmed/36777069 http://dx.doi.org/10.1093/crocol/otaa093

Ejemplares similares

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
por: Bhat, Shubha, et al.
Publicado: (2020)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Optimizing Medication Access and Use in Inflammatory Bowel Disease: The Roles and Impact of Clinical Pharmacists and Pharmacy Technicians
por: Bhat, Shubha
Publicado: (2023)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2018)

Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
por: Martínez-Feito, Ana, et al.
Publicado: (2020)

The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta
por: Kaplan, Gilaad G, et al.
Publicado: (2020)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
por: Huoponen, Saara, et al.
Publicado: (2020)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
por: Massimi, Davide, et al.
Publicado: (2021)

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
por: Fischer, Sarah, et al.
Publicado: (2021)

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
por: Pierik, Marieke J, et al.
Publicado: (2021)

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
por: Panaccione, Remo
Publicado: (2021)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
por: Nakagawa, Tomoo, et al.
Publicado: (2019)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics
por: Limdi, Jimmy K, et al.
Publicado: (2021)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
por: Strik, Anne S., et al.
Publicado: (2019)

Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study
por: Fisher, Anat, et al.
Publicado: (2023)

Chronic Inflammatory Demyelinating Polyneuropathy After Therapy With Infliximab Biosimilar
por: Larson, Jessica, et al.
Publicado: (2023)

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
por: Abdalla, Abuelmagd, et al.
Publicado: (2017)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
por: Pękala, Anna, et al.
Publicado: (2021)

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar
por: Meijboom, Rosanne W., et al.
Publicado: (2023)

Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review
por: Bashir, Naazish S., et al.
Publicado: (2023)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
por: Yazici, Yusuf, et al.
Publicado: (2018)

Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
por: Bernard, Edmond-Jean, et al.
Publicado: (2020)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_etqqgpv2q9jpc3m5j6ciq7leps